Abstract:Abstract Background Multiple myeloma (MM) is the most common malignant hematological disease in the people worldwide. Glaucocalyxin A (GLA) is a bioactive ent-kauranoid diterpenoid, that is derived from Rabdosia japonica var . GLA has been demonstrated that it had various pharmacological activities, such as anti-coagulation, anti-bacterial, anti-tumor, anti-inflammation, antioxidant activities. Although GLA has effective anti-tumor properties, its effects on multiple myeloma remain unclear. The aim of this study was to examine the possible anti-cancer effects of GLA and their molecular mechanisms on MM cells in vitro and in vivo. Methods To evaluate the role of GLA on the proliferation of MM cells in vitro and in vivo, we used MTT method to detect the role of GLA on the proliferation of MM cells. Cell apoptosis and cell cycle assay were evaluated by flow cytometry. Protein expressions in GLA-treated and untreated MM cells were evaluated by western blot analyses. MM xenograft nude mice model was used to investigate the role of GLA on the proliferation of MM cells in vivo. IHC assay was used to examine the role of GLA on the MM xenograft model in vivo. Results In the present study, we firstly reported the potent anti-myeloma activity of GLA on MM cells. We found that GLA could induce apoptosis in vitro and in vivo. GLA could inhibit the phosphorylation of the signal transducer and activator of transcription 3 (STAT3) and downregulate interleukin IL-6 induced STAT3 phosphorylation in MM. Overexpression of STAT3 could significantly prevent apoptosis induced by GLA; while knockdown of STAT3 enhanced it. Moreover, GLA could inhibit cell proliferation by inducing the cell cycle arrest. GLA reduced the expression of cell cycle-related proteins CCNB1, CCND1, CCND2, and CCND3 and increased the expression of p21 in MM cell lines. In addition, in the MM xenograft nude mice model, GLA exhibited very good anti-myeloma activity. Administration of GLA almost completely inhibited tumor growth within 19 days without physical toxicity. And the IHC results showed GLA significantly inhibited cell proliferation and interfered STAT3 pathway on MM xenograft model tumor tissues. Conclusions Taken together, our present research indicated that GLA inhibits the MM cell proliferation, induces MM cell apoptosis and cell cycle arrest through blocking the activation of STAT3 pathway. Thus, GLA may be a potential therapeutic candidate for MM patients in the future.

Dual Inhibition of MYC and SLC39A10 by a Novel Natural Product STAT3 Inhibitor Derived from Chaetomium Globosum Suppresses Tumor Growth and Metastasis in Gastric Cancer.

HJC0152, a Novel STAT3 Inhibitor with Promising Anti-Tumor Effect in Gastric Cancer

BP‑1‑102 Exerts an Antitumor Effect on the AGS Human Gastric Cancer Cell Line Through Modulating the STAT3 and MAPK Signaling Pathways.

The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts

Cucurbitacin B inhibits gastric cancer progression by suppressing STAT3 activity

Activation of STAT3 in Human Gastric Cancer Cells Via Interleukin (Il)-6-type Cytokine Signaling Correlates with Clinical Implications

S3I-201 Derivative Incorporating Naphthoquinone Unit As Effective STAT3 Inhibitors: Design, Synthesis and Anti-Gastric Cancer Evaluation

Inhibition of STAT3 Signaling Pathway by Terphenyllin Suppresses Growth and Metastasis of Gastric Cancer

Methylomics Analysis Identifies a Putative STAT3 Target, SPG20, As a Noninvasive Epigenetic Biomarker for Early Detection of Gastric Cancer

Discovery of Benzochalcone Derivative As a Potential Antigastric Cancer Agent Targeting Signal Transducer and Activator of Transcription 3 (STAT3).

Cryptotanshinone Potentiates the Antitumor Effects of Doxorubicin on Gastric Cancer Cells Via Inhibition of STAT3 Activity.

The potential effect and mechanism of Saikosaponin A against gastric cancer

Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer

Discovery of potent STAT3 inhibitors using structure-based virtual screening, molecular dynamic simulation, and biological evaluation

A dual MET/AXL small‐molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment

Glaucocalyxin A Inhibits the Malignancies of Gastric Cancer Cells by Downregulating MDM2 and RNF6 via MiR-3658 and the SMG1-UPF mRNA Decay Pathway

Induction, growth, drug resistance, and metastasis: A comprehensive summary of the relationship between STAT3 and gastric cancer

Constitutive Activation of STAT3 is Predictive of Poor Prognosis in Human Gastric Cancer

Glaucocalyxin A suppresses multiple myeloma progression in vitro and in vivo through inhibiting the activation of STAT3 signaling pathway

A Novel Biological Activity of the STAT3 Inhibitor Stattic in Inhibiting Glutathione Reductase and Suppressing the Tumorigenicity of Human Cervical Cancer Cells via a ROS-Dependent Pathway

S1PR1 Predicts Patient Survival and Promotes Chemotherapy Drug Resistance in Gastric Cancer Cells Through STAT3 Constitutive Activation